We are developing nanoparticle drugs based on a very limited understanding of how nanoparticles are transported from vascular circulation into solid tumors. We do not know what cell types, microenvironments, or biological molecules mediate this effect in humans, what cell types take up delivered agents, and how our animal models correlate with human tumors in these respects. Mechanistic studies and comparative pathology studies (between species and between tumor types/subtypes) are needed for successful translation of basic studies into efficacious clinic treatments and to predict which cancer types will be most responsive to specific nanoparticle treatments.
Voting on Ideas
Vote for your favorite ideas by clicking on the up arrow.To undo an upvote, simply click the arrow again. This second click removes your vote.